Inovio HBV immunotherapy candidate INO-1800 shows encouraging action in early-stage study; shares ahead 5 … – Seeking Alpha
|
Inovio HBV immunotherapy candidate INO-1800 shows encouraging action in early-stage study; shares ahead 5 …
Seeking Alpha Inovio Pharmaceuticals (NYSEMKT:INO) is up 5% premarket on light volume on the heels of its announcement of positive preliminary results from a Phase 1 clinical trial assessing the safety, tolerability and immunogenicity of hepatitis B virus (HBV) DNA … |
